ReviewThorax2022
Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy.
Review in Thorax, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 1 synthesis or guideline pooled it, 108 citations in OpenAlex.
- Systemic treatment of immune checkpoint inhibitor-induced psoriasis: Inference-based guidance.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Pooled it
- Pembrolizumab and reactivation of TB: is there a link?IJTLD open · 2026Article
- Single-cell transcriptomics reveal PD-1-loss-driven immune dysregulation of pulmonary lymphocytes during earlyMicrobiology spectrum · 2026Article
- The impact of immune checkpoint inhibitors on infection in patients with solid malignancies: a systematic review and meta-analysis of randomised controlled trials.EClinicalMedicine · 2026Article
- Article
- Hemostasis at the edge between physiology and cancer.Internal and emergency medicine · 2026Review
- Article
- Post-treatment infection prediction in CLL using domain adaptation of lymphoma electronic health records.Acta oncologica (Stockholm, Sweden) · 2026Article
- Engineering bacteriophages for gut health: precision antimicrobials and beyond.Journal of nanobiotechnology · 2026Review
- Disseminated tuberculosis secondary to polymicrobial co-infection following long-term immunotherapy for sarcomatoid mesothelioma: A case report.Respiratory medicine case reports · 2026Article
- Case Report: Rare Multidrug-Resistant Enterobacter Cloacae Complicated by Invasive Pulmonary Aspergillosis in an Elderly Patient with Advanced Lung Adenocarcinoma Treated with Osimertinib.Infection and drug resistance · 2026Article
- The incidence and risk factors of pulmonary infection complications in lung cancer patients treated with immune checkpoint inhibitors.BMC cancer · 2025Article
- Cytokine release syndrome complicated with sepsis induced by tislelizumab in a patient with advanced hepatocellular carcinoma: A case report.Human vaccines & immunotherapeutics · 2025Article
- Beyond Tumor Immunity: The Disruption of Endocrine and Infectious Homeostasis by Immune Checkpoint Inhibitors.International journal of molecular sciences · 2025Review
- Comparative efficacy and safety of PD-1/PD-L1 inhibitors versus docetaxel in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.Journal of thoracic disease · 2025Article
- The value of second-generation gene sequencing in lung cancer immunotherapy with concurrent infections.BMC cancer · 2025Article
- Article
- Article
- Review Article: Liver Transplantation for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors.Alimentary pharmacology & therapeutics · 2025Review
- Population-Based Analysis of the Risk of Mycobacterial Infections Associated With Immune Checkpoint Inhibitors.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
Abstract
Immune checkpoint inhibitors (ICIs) have revolutionised cancer treatment. However, immune-related adverse events (irAEs) are a common side effect which can mimic infection. Additionally, treatment of irAEs with corticosteroids and other immunosuppressant agents can lead to opportunistic infection, which we have classed as immunotherapy infections due to immunosuppression. However, emerging reports demonstrate that some infections can be precipitated by ICIs in the absence of immunosuppressive treatment, in contrast to the majority of reported cases. These infections are characterised by a dysregulated inflammatory immune response, and so we propose they are described as immunotherapy infections due to dysregulated immunity. This review summarises the rapidly emerging evidence of these phenomena and proposes a new framework for considering infection in the context of cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.